

Rev 1: September 2018  
FSN Ref: 2102-07-FSN

FSCA Ref: 2102-07-FSCA



Date: 06.May.2021

**Urgent Field Safety Notice**  
**AUTOSELECTOR**

For Attention of: Swissmedic, Schweizerisches Heilmittelinstitut and Dutch Health and Youth Care Inspectorate (IGJ)

Contact Information  
Name: Ace-medical (Manufacturer)  
Address: 33, Naeyugil 124beon-gil, Deogyang-gu, Goyang-si, Gyeonggi-do, Republic of Korea  
Postcode: 10264  
Phone: +82-31-960-9263  
E-mail.: dykim@ace-medical.com

**Urgent Field Safety Notice (FSN)**  
**AUTOSELECTOR**  
**Leak in the selector module**



<b>1. Information on Affected Devices*</b>	
1.	<p>1. <b>Device Type(s)*</b></p> <p>Infusion pump, manually-operated, and sterilized product</p>
1.	<p>2. <b>Commercial name(s)</b></p> <p>AUTOSELECTOR (550mL / B-type)</p>
1.	<p>3. <b>Unique Device Identifier(s) (UDI-DI)</b></p> <p>N/A</p>
1.	<p>4. <b>Primary clinical purpose of device(s)*</b></p> <p>The AutoSelector is intended for continuous and/or intermittent infusion of medication for general infusion use including antibiotic, chemotherapy and pain management therapies.</p>
1.	<p>5. <b>Device Model/Catalogue/part number(s)*</b></p> <p>AFLC-B</p>
1.	<p>6. <b>Software version</b></p> <p>N/A</p>
1.	<p>7. <b>Affected serial or lot number range</b></p> <p>A200804-PSCFB000CH-1, A200805-PSCFB000CH-1</p>
1.	<p>8. <b>Associated devices</b></p> <p>N/A</p>

<b>2 Reason for Field Safety Corrective Action (FSCA)*</b>	
2.	<p>1. <b>Description of the product problem*</b></p> <p>Leak in the selector module.</p>
2.	<p>2. <b>Hazard giving rise to the FSCA*</b></p> <p>There was no harm to a patient. However as a result of customer complaint product tests, reported condition was verified. Since we identified the root cause and prevent the same customer complaint, we issue the FSCA.</p>
2.	<p>3. <b>Probability of problem arising</b></p> <p>To prevent the same customer complaint arising, Ace-medical will remove the product LOT number A200804-PSCFB000CH-1 and A200805-PSCFB000CH-1.</p>

2.	<b>4. Predicted risk to patient/users</b>
	If the leaking selector module is attached to the patient, drug can be injected abnormally (At low risk).
2.	<b>5. Further information to help characterise the problem</b>
	N/A
2.	<b>6. Background on Issue</b>
	A number of Autoselectors were returned as customer complaints products. And through the tests of them, Ace-medical found a problem on a material(LOT number A200715) which is used on product LOT number A200804-PSCFB000CH-1 and A200805-PSCFB000CH-1.
2.	<b>7 Other information relevant to FSCA</b>
	N/A

<b>3. Type of Action to mitigate the risk*</b>	
3.	<p><b>1. Action To Be Taken by the User*</b></p> <p><input type="checkbox"/> Identify Device   <input type="checkbox"/> Quarantine Device   <input type="checkbox"/> Return Device   <input checked="" type="checkbox"/> Destroy Device</p> <p><input type="checkbox"/> On-site device modification/inspection</p> <p><input type="checkbox"/> Follow patient management recommendations</p> <p><input type="checkbox"/> Take note of amendment/reinforcement of Instructions For Use (IFU)</p> <p><input type="checkbox"/> Other                      <input type="checkbox"/> None</p> <p>Provide further details of the action(s) identified.</p>
3.	<p>2. By when should the action be completed?</p> <p style="text-align: right;">The expected date is mid-May</p>
3.	<p>3. Particular considerations for:                      MDD</p> <p>Is follow-up of patients or review of patients' previous results recommended? No, as Ace-medical chooses to destroy (remove) the product, we do not need follow-up of patients.</p>
3.	<p>4. Is customer Reply Required? * (If yes, form attached specifying deadline for return)</p> <p style="text-align: right;">No</p>

3.	<b>5. Action Being Taken by the Manufacturer</b>  <input checked="" type="checkbox"/> Product Removal <input type="checkbox"/> On-site device modification/inspection <input type="checkbox"/> Software upgrade <input type="checkbox"/> IFU or labelling change <input type="checkbox"/> Other <input type="checkbox"/> None	
3	6. By when should the action be completed?	The expected date is mid-May
3.	7. Is the FSN required to be communicated to the patient /lay user?	No
3	8. If yes, has manufacturer provided additional information suitable for the patient/lay user in a patient/lay or non-professional user information letter/sheet?	

<b>4. General Information*</b>	
4.	1. FSN Type* Update
4.	2. For updated FSN, reference number and date of previous FSN 2102-07-FSN, 28. April. 2021
4.	3. For Updated FSN, key new information as follows: N/A
4.	4. Further advice or information already expected in follow-up FSN? * No
4.	5. If follow-up FSN expected, what is the further advice expected to relate to: N/A
4.	6. Anticipated timescale for follow-up FSN N/A
4.	7. Manufacturer information (For contact details of local representative refer to page 1 of this FSN)
	a. Company Name Ace-medical
	b. Address 33, Naeyugil 124beon-gil, Deogyang-gu, Goyang-si, Gyeonggi-do, Republic of Korea
	c. Website address www.ace-medical.com
4.	8. The Competent (Regulatory) Authority of your country has been informed about this communication to customers. *No
4.	9. List of attachments/appendices: N/A
4.	10. Name/Signature <div style="text-align: right;">  Quality Management Manager   </div>
<b>Transmission of this Field Safety Notice</b>	

Note: Fields indicated by \* are considered necessary for all FSNs. Others are optional.